<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65327">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255422</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 408-C-1403</org_study_id>
    <nct_id>NCT02255422</nct_id>
  </id_info>
  <brief_title>RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR</brief_title>
  <official_title>A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mitochondrial myopathies are a multisystemic group of disorders that are characterized by a
      wide range of biochemical and genetic mitochondrial defects and variable modes of
      inheritance. Currently there are no effective treatments for this disease. Despite the
      heterogeneous myopathy phenotypes, a unifying feature of mitochondrial myopathies is that
      the pathogenic mtDNA mutations and/or nuclear mutations of the electron transport chain
      invariably lead to dysfunctional mitochondrial respiration. This reduction in mitochondrial
      respiration leads to a reduced ability to produce cellular adenosine triphosphate (ATP),
      often resulting in muscle weakness, exercise intolerance, and fatigue in patients with
      mitochondrial myopathies.

      RTA 408 is a potent activator of Nrf2 and inhibitor of NF κB (nuclear factor
      kappa-light-chain-enhancer of activated B cells), and thus induces an antioxidant and
      anti-inflammatory phenotype. Several lines of evidence suggest that Nrf2 activation can
      increase mitochondrial respiration and biogenesis. Collectively, available data suggest that
      the ability of RTA 408 to activate Nrf2 and induce its target genes could potentially
      improve muscle function, oxidative phosphorylation, antioxidant capacity, and mitochondrial
      biogenesis in patients with mitochondrial myopathies.

      Part 1: The first part of this study will be a randomized, placebo-controlled, double-blind,
      dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in
      patients with mitochondrial myopathies.

      Part 2: The second part of this study is a randomized, placebo-controlled, double-blind,
      parallel study to evaluate the safety, efficacy, and pharmacodynamics of up to 2 dose levels
      of omaveloxolone (RTA 408) in patients with mitochondrial myopathies. Eligible patients in
      Part 2 will be randomized 1:1:1 to receive omaveloxolone (RTA 408) (at one of 2 doses chosen
      from Part 1), or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the change of peak workload (in watts/kg) during exercise testing</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the change in distance walked during a 6-minute walk test</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>MItochondrial Myopathies</condition>
  <arm_group>
    <arm_group_label>omaveloxolone Capsules 2.5 mg and 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omaveloxolone Capsules 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omaveloxolone Capsules 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omaveloxolone Capsules TBD mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, TBD mg taken orally once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omaveloxolone Capsules 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omaveloxone Capsules 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omaveloxone Capsules 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone capsules, 2.5 mg</intervention_name>
    <arm_group_label>omaveloxolone Capsules 2.5 mg and 5 mg</arm_group_label>
    <other_name>RTA 408 Capsules 2.5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omaveloxolone capsules, 5 mg</intervention_name>
    <arm_group_label>omaveloxolone Capsules 2.5 mg and 5 mg</arm_group_label>
    <other_name>RTA 408 capsules, 5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omaveloxolone capsules, 10 mg</intervention_name>
    <arm_group_label>omaveloxolone Capsules 10 mg</arm_group_label>
    <other_name>RTA 408, 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <arm_group_label>Placebo Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omaveloxolone capsules, 20 mg</intervention_name>
    <arm_group_label>omaveloxolone Capsules 20 mg</arm_group_label>
    <other_name>RTA 408 capsules, 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omaveloxolone capsules, TBD mg</intervention_name>
    <arm_group_label>omaveloxolone Capsules TBD mg</arm_group_label>
    <other_name>RTA 408 capsules, TBD mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omaveloxolone capsules, 40 mg</intervention_name>
    <arm_group_label>omaveloxolone Capsules 40 mg</arm_group_label>
    <other_name>RTA 408 capsules, 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omaveloxolone capsules, 80 mg</intervention_name>
    <arm_group_label>omaveloxone Capsules 80 mg</arm_group_label>
    <other_name>RTA 408 capsules, 80 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omaveloxolone capsules, 160 mg</intervention_name>
    <arm_group_label>omaveloxone Capsules 160 mg</arm_group_label>
    <other_name>RTA 408 capsules, 160 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have mitochondrial myopathy as evidenced by the following 2 criteria (must meet
             both):

               1. Have a history of exercise intolerance with or without weakness and/or
                  progressive exercise intolerance (in which modest exercise typically provokes
                  heaviness, weakness, aching of active muscles, or tachycardia)

               2. Have a known primary mitochondrial DNA mutation or a nuclear DNA defect that is
                  associated with reduced activity of at least 1 mitochondrially encoded
                  respiratory chain complex

          2. Be male or female and ≥18 years of age and ≤75 years of age

          3. Have no changes to exercise regimen within 30 days prior to Study Day 1 and be
             willing to remain on the same exercise regimen during the 16-week study period

          4. Have the ability to complete maximal exercise testing

          5. Have a peak workload during maximal exercise testing of ≤ 1.5 W/kg

          6. Be able to swallow capsules

        Exclusion Criteria:

          1. Have uncontrolled diabetes (HbA1c &gt;11.0%)

          2. Have B-type natriuretic peptide level &gt;200 pg/mL

          3. Have a history of clinically significant left-sided heart disease and/or clinically
             significant cardiac disease

          4. Have known active fungal, bacterial, and/or viral infection, including human
             immunodeficiency virus or hepatitis virus (B or C)

          5. Have known or suspected active drug or alcohol abuse

          6. Have clinically significant abnormalities of clinical hematology or biochemistry,
             including but not limited to elevations greater than 1.5 times the upper limit of
             normal of aspartate aminotransferase, alanine aminotransferase, or creatinine

          7. Have any abnormal laboratory test value or serious pre-existing medical condition
             that, in the opinion of the investigator, would put the patient at risk by study
             enrollment

          8. Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to
             take any of these drugs during the time of study participation:

               1. Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide,
                  midazolam, sildenafil)

               2. Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin)

          9. Have participated in any other interventional clinical study within 30 days prior to
             Study Day 1

         10. Have a cognitive impairment that may preclude ability to comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bonitati</last_name>
      <phone>310-825-3264</phone>
      <email>mbonitati@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Perry Shieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Kelly</last_name>
      <phone>617-724-7726</phone>
      <email>elkelly@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Amel Karaa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Tonni</last_name>
      <phone>330-543-4734</phone>
      <email>HTonni@chmca.org</email>
    </contact>
    <investigator>
      <last_name>Bruce Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyntovia Hylton</last_name>
      <phone>267-426-0241</phone>
      <email>hyltonl@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Marni Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Graham</last_name>
      <phone>412-692-3476</phone>
      <email>michele.graham@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Gerard Vockley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitute for Exercise &amp; Environmental Medicine</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Newby</last_name>
      <phone>214-345-4655</phone>
      <email>martanewby@texashealth.org</email>
    </contact>
    <investigator>
      <last_name>Ron Haller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Feldman, RN, MSN</last_name>
      <phone>832-822-4301</phone>
      <email>bmfeldma@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Fernando Scaglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sreejeta Dasgupta</last_name>
      <phone>713-500-5757</phone>
      <email>sreejeta.dasgupta@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Mary Kay Koenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuromuscular Clinic, Rigshospitalet, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Lindhardt Madsen</last_name>
      <phone>+45-3545 6135</phone>
      <email>karen.Lindhardt.Madsen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Karen Madsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 14, 2016</lastchanged_date>
  <firstreceived_date>September 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>omaveloxolone</keyword>
  <keyword>RTA 408 capsules</keyword>
  <keyword>mitochondrial myopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Mitochondrial Myopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
